Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Ransohoff

Showing results (31-40 of 137) with videos related to

Pageof 14
Sort By:
Scandinavian Journal of Immunology|June 28, 2003
Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitisA R Glabinski, B Bielecki, R M Ransohoff
Lancet (London, England)|May 26, 1990
Vitamin B12 deficiency and multiple sclerosisR M Ransohoff, D W Jacobsen, R Green
Journal of Neuroscience Research|September 15, 1996
Transcriptional regulation of chemokine gene expression in astrocytesS Majumder, L Z Zhou, R M Ransohoff
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1999
TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNAY Han, Z H Zhou, R M Ransohoff
Journal of Computer Assisted Tomography|July 1, 1995
Unusual long-standing Gd-DTPA enhancement in a chronic progressive myelopathyB Weinstock-Guttman, J S Ross, R M Ransohoff
Neurology|April 1, 1990
Noncommunicating syringomyelia in multiple sclerosis: detection by magnetic resonance imagingR M Ransohoff, G J Whitman, M A Weinstein
Cleveland Clinic Journal of Medicine|January 1, 1992
Experimental therapies for multiple sclerosis: current statusD E Goodkin, R M Ransohoff, R A Rudick
Cleveland Clinic Journal of Medicine|May 1, 1992
Pharmacotherapy of multiple sclerosis: current statusR A Rudick, D E Goodkin, R M Ransohoff
Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1997
Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinomaR P Kinkel, R A Rudick, R M Ransohoff
Der Nervenarzt|October 11, 2003
[Chemokine--possible new options for the treatment of multiple sclerosis]C Trebst, R M Ransohoff, A Windhagen, et al.
Pageof 14

Showing results (31-40 of 137) with videos related to

Sort By:
Pageof 14
Scandinavian Journal of Immunology|June 28, 2003
Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitisA R Glabinski, B Bielecki, R M Ransohoff
Lancet (London, England)|May 26, 1990
Vitamin B12 deficiency and multiple sclerosisR M Ransohoff, D W Jacobsen, R Green
Journal of Neuroscience Research|September 15, 1996
Transcriptional regulation of chemokine gene expression in astrocytesS Majumder, L Z Zhou, R M Ransohoff
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1999
TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNAY Han, Z H Zhou, R M Ransohoff
Journal of Computer Assisted Tomography|July 1, 1995
Unusual long-standing Gd-DTPA enhancement in a chronic progressive myelopathyB Weinstock-Guttman, J S Ross, R M Ransohoff
Neurology|April 1, 1990
Noncommunicating syringomyelia in multiple sclerosis: detection by magnetic resonance imagingR M Ransohoff, G J Whitman, M A Weinstein
Cleveland Clinic Journal of Medicine|January 1, 1992
Experimental therapies for multiple sclerosis: current statusD E Goodkin, R M Ransohoff, R A Rudick
Cleveland Clinic Journal of Medicine|May 1, 1992
Pharmacotherapy of multiple sclerosis: current statusR A Rudick, D E Goodkin, R M Ransohoff
Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1997
Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinomaR P Kinkel, R A Rudick, R M Ransohoff
Der Nervenarzt|October 11, 2003
[Chemokine--possible new options for the treatment of multiple sclerosis]C Trebst, R M Ransohoff, A Windhagen, et al.
Pageof 14